Ball Lunla / ShutterstockPfizer and BioNTech said they expect to produce up to 50 million vaccine doses globally in 2020 and up to 1.3 billion doses in 2021. (Ball Lunla / Shutterstock)
Pfizer says that more interim results from its ongoing coronavirus vaccine study suggest the shots are 95 percent effective and that the vaccine protects older people most at risk of dying from COVID-19.
Wednesday’s announcement from Pfizer and its German partner BioNTech, just a week after revealing the first promising preliminary results, comes as the team is preparing within days to formally ask U.S. regulators to allow emergency use of the vaccine.
They also have begun “rolling submissions” for the vaccine with regulators in Europe, the United Kingdom and Canada and soon will add this new data.
Pfizer and BioNTech had initially estimated the vaccine was more than 90 percent effective after 94 infections had been